QualityStocks would like to highlight Anthera Pharmaceuticals Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.
In the company’s news yesterday,
Anthera Pharmaceuticals Inc. announced positive interim biomarker data from the PEARL-SC phase 2b clinical study to evaluate the therapeutic benefit of blisibimod injections in patients with lupus.
The study enrolled 547 patients in 11 countries and 72 clinical sites around the world to test the efficacy, safety and tolerability of blisibimod.
Consistent with previous clinical studies, the on-going PEARL-SC study indicates that weekly and monthly doses of blisibimod significantly reduced B-cells, which is valuable data because elevations in these cells have been associated with an increased risk of disease activity in lupus patients.
"We believe reductions of B-cells in the PEARL-SC study will correlate to a reduction in disease activity in patients treated with blisibimod," Colin Hislop, MD, chief medical officer and senior vice president of Anthera stated in the press release. "This analysis demonstrates that the selected weekly and monthly blisibimod doses resulted in an appropriate biological response. If confirmed with positive clinical outcomes from the PEARL-SC study, these data will provide guidance for the design of our phase 3 clinical studies and allow us to differentiate blisibimod from other available BAFF inhibitors for the treatment of lupus."
Anthera said it expects final results from the PEARL-SC clinical study in the second quarter of 2012.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
